News | December 31, 2025
Transcenta teams up with EirGenix to revolutionise biologics manufacturing
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Harbour BioMed brings advanced antibody discovery platforms to the table
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
Subscribe To Our Newsletter & Stay Updated
